Verustat Expands Service With DCT Support
Verustat has expanded its services to provide multiple levels of support for decentralized clinical trials (DCT). Verustat's customizable SELECT DCT offering is a streamlined solution that can offer increased compliance, stability, and accuracy.
The DCT program was designed to enhance the patient experience and improve compliance at the patient’s home. Each DCT can be customized to the patient’s requirements. Service offerings include Verustat’s RPM platform, telemedicine visits, medical peripheral hardware sourcing, multiple communication methods, global customs management, Tier 2 technical support, and equipment leasing.
Read more about Verustat here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
